
The co-founder, chief science officer, and chairman at Longeveron discusses the findings from the phase 2a trial CLEARMIND, as well as next steps to developing the therapy Lomecel-B.


The co-founder, chief science officer, and chairman at Longeveron discusses the findings from the phase 2a trial CLEARMIND, as well as next steps to developing the therapy Lomecel-B.

The findings indicate that zoster vaccine recombinant reduced dementia risk by 17% in an analysis of over 200,000 patients.

Joshua Hare describes how Lomecel-B addresses neuroinflammation, unlike other treatments which typically target amyloid disposition.

The study also found that there were no associations with increased dementia risk when anxiety resolved.

Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.

The findings also demonstrate that body dysmorphic disorder is also associated with high levels of comorbid psychopathology, risk, and psychosocial impairment.

Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.

The authors note that the oral, at-home treatment can be a better alternative for patients by reducing inconveniences that come with the injectable and nasal administration methods.

Fish are rich in nutrients that aid in brain development, and the model can help provide more guidance for pregnant individuals when consuming seafood.

Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.

The findings suggest that exploring gender identity is a normal part of adolescent development for some youths.

According to the authors, this vulnerability may stem from either sporadic occurrences of intergenerational chains of childhood abuse.

Tune into this episode of “Public Health Matters” to hear Dr. Bolu Oladini’s unconventional journey within pharmacy, his passion for mental health, and how artificial intelligence is beginning to be integrated into health care and everyday life.

The supplemental new drug application (sNDA) for brexpiprazole is accepted by the FDA for treatment of patients with post-traumatic stress disorder (PTSD).

Autism spectrum disorder was also evaluated in the analysis, but further research is required to determine a possible association with relative age effect.

Creating a supportive environment and staying informed on the latest research can be significant when supporting patients in the LGBTQ+ community, notes Olivia Buckoski, PharmD, AAHIVP, HIVPCP.

Anti-amyloid antibody administration decreased plaque volume in clinical trials of patients with early AD, indicating that passive immunotherapies could be a promising treatment for the disease.

Tune into this episode of “Public Health Matters” to hear Dr. Bolu Oladini’s unconventional journey within pharmacy, his passion for mental health, and how artificial intelligence is beginning to be integrated into health care and everyday life.

The default-mode network method, which was analyzed using functional magnetic resonance imaging scans, was approximately 80% accurate when predicting dementia up to 9 years prior to a diagnosis.

The authors noted that these networks have a significant role in intellectual ability, physical coordination, working memory, emotional processing, and overall mental health.

Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.

Tune into this special episode of “Public Health Matters” to hear Emma White, the founder and president of the nonprofit organization Life Is Worth It, discuss her mental health journey and how she used it to educate adolescents, teenagers, and young adults on mental wellness.

The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.

The treatment is indicated for adult patients with tardive dyskinesia and Huntington disease chorea, with tablets now available in 4 different doses.

Tune into this special episode of “Public Health Matters” to hear Emma White, the founder and president of the nonprofit organization Life Is Worth It, discuss her mental health journey and how she used it to educate adolescents, teenagers, and young adults on mental wellness.